Increased ER Stress After Experimental Ischemic Optic Neuropathy and Improved RGC and Oligodendrocyte Survival After Treatment With Chemical Chaperon.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 05 2019
Historique:
entrez: 7 5 2019
pubmed: 7 5 2019
medline: 11 10 2019
Statut: ppublish

Résumé

Increased endoplasmic reticulum (ER) stress is one of the earliest subcellular changes in neuro-ophthalmic diseases. In this study, we investigated the expression of key molecules in the ER stress pathways following nonarteritic anterior ischemic optic neuropathy (AION), the most common acute optic neuropathy in adults over 50, and assessed the impact of chemical chaperon 4-phenylbutyric acid (4-PBA) in vivo. We induced AION using photochemical thrombosis in adult mice and performed histologic analyses of key molecules in the ER stress pathway in the retina and optic nerve. We also assessed the effects of daily intraperitoneal injections of 4-PBA after AION. In the retina at baseline, there was low proapoptotic transcriptional regulator C/EBP homologous protein (CHOP) and high prosurvival chaperon glucose-regulated protein 78 (GRP78) expression in retinal ganglion cells (RGCs). One day after AION, there was significantly increased CHOP and reduced GRP78 expressions in the ganglion cell layer. In the optic nerve at baseline, there was little CHOP and high GRP78 expression. One day after AION, there was significantly increased CHOP and no change in GRP78 expression. Treatment immediately after AION using daily intraperitoneal injection of chemical chaperone 4-PBA for 19 days significantly rescued Brn3A+ RGCs and Olig2+ optic nerve oligodendrocytes. We showed for the first time that acute AION resulted in increased ER stress and differential expression of ER stress markers CHOP and GRP78 in the retina and optic nerve. Rescue of RGCs and oligodendrocytes with 4-PBA provides support for ER stress reduction as possible treatment for AION.

Identifiants

pubmed: 31060051
pii: 2733124
doi: 10.1167/iovs.18-24890
pmc: PMC6735778
doi:

Substances chimiques

Ddit3 protein, mouse 0
Endoplasmic Reticulum Chaperone BiP 0
Heat-Shock Proteins 0
Hspa5 protein, mouse 0
Molecular Chaperones 0
Phenylbutyrates 0
Transcription Factor CHOP 147336-12-7
4-phenylbutyric acid 7WY7YBI87E

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1953-1966

Subventions

Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023295
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY024932
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028106
Pays : United States

Références

Physiol Genomics. 2005 May 11;21(3):389-95
pubmed: 15769908
J Clin Invest. 2011 Sep;121(9):3542-53
pubmed: 21821918
Exp Eye Res. 2014 Aug;125:30-40
pubmed: 24792589
Invest Ophthalmol Vis Sci. 2013 Dec 05;54(13):7952-61
pubmed: 24065807
Science. 2007 Nov 9;318(5852):944-9
pubmed: 17991856
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2985-92
pubmed: 18326695
Prog Retin Eye Res. 2011 May;30(3):167-87
pubmed: 21376134
Trans Am Ophthalmol Soc. 2000;98:203-20; discussion 221-2
pubmed: 11190024
Methods. 2005 Apr;35(4):373-81
pubmed: 15804610
Exp Eye Res. 2010 Aug;91(2):286-92
pubmed: 20621651
PLoS One. 2013 Nov 15;8(11):e78058
pubmed: 24260105
Exp Diabetes Res. 2012;2012:589589
pubmed: 22216020
Invest Ophthalmol Vis Sci. 2012 May 31;53(6):3241-9
pubmed: 22491413
Int Rev Cytol. 2003;230:263-90
pubmed: 14692684
J Cell Biol. 2005 May 23;169(4):603-12
pubmed: 15911877
Ophthalmology. 1987 Aug;94(8):1020-8
pubmed: 3658362
Eye (Lond). 2011 Jun;25(6):809-17
pubmed: 21475310
Invest Ophthalmol Vis Sci. 2015 May;56(5):2790-7
pubmed: 25414186
Invest Ophthalmol Vis Sci. 2012 Mar 21;53(3):1557-65
pubmed: 22328638
Brain Res. 2010 Jul 30;1346:43-51
pubmed: 20573599
J Neuroophthalmol. 2003 Jun;23(2):157-63
pubmed: 12782932
J Neurosci. 2016 May 25;36(21):5891-903
pubmed: 27225776
J Neurochem. 2015 Feb;132(3):342-53
pubmed: 25351847
Clin Ophthalmol. 2017 Oct 11;11:1825-1834
pubmed: 29066860
J Pediatr. 2013 Jun;162(6):1228-34, 1234.e1
pubmed: 23324524
J Vasc Surg. 2010 Dec;52(6):1580-6
pubmed: 20843623
PLoS One. 2008 Apr 30;3(4):e2055
pubmed: 18446207
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4153-62
pubmed: 14507856
J Neurosci. 2016 May 25;36(21):5808-19
pubmed: 27225770
Glia. 2005 Dec;52(4):261-75
pubmed: 16001425
Cell Death Dis. 2012 Feb 16;3:e272
pubmed: 22337234
Neurosci Lett. 2011 Aug 26;501(2):102-6
pubmed: 21767604
Nat Genet. 2014 Feb;46(2):152-60
pubmed: 24336168
Histol Histopathol. 2008 Nov;23(11):1409-16
pubmed: 18785123
Mol Neurodegener. 2017 May 25;12(1):42
pubmed: 28545479
Invest Ophthalmol Vis Sci. 2011 Nov 11;52(12):8754-62
pubmed: 22003119
Nature. 2016 Jan 21;529(7586):326-35
pubmed: 26791723
Cell Death Dis. 2017 Jul 20;8(7):e2936
pubmed: 28726788
Neuroscience. 2015 Mar 19;289:214-23
pubmed: 25592431
Am J Transl Res. 2016 Apr 15;8(4):1864-75
pubmed: 27186310
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1778-90
pubmed: 19098320
Mol Vis. 2008;14:2171-9
pubmed: 19052651
J Neurosci Res. 2015 Nov;93(11):1675-83
pubmed: 26271210
Shock. 2013 May;39(5):433-9
pubmed: 23481493
Brain Res. 2011 Jan 25;1370:227-37
pubmed: 21075086
Drugs R D. 2011 Sep 1;11(3):227-49
pubmed: 21902286
Prog Retin Eye Res. 2009 Jan;28(1):34-62
pubmed: 19063989
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):527-32
pubmed: 26868755
Neuron. 2012 Feb 9;73(3):445-52
pubmed: 22325198
Mol Pharmacol. 2004 Oct;66(4):899-908
pubmed: 15226415
Apoptosis. 2012 Mar;17(3):278-88
pubmed: 22120956
Invest Ophthalmol Vis Sci. 2013 Sep 05;54(9):5981-8
pubmed: 23887804
FEBS Lett. 2009 May 6;583(9):1521-7
pubmed: 19364508
Proc Natl Acad Sci U S A. 2014 May 6;111(18):6804-9
pubmed: 24753614
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2716-25
pubmed: 16043843
Antioxid Redox Signal. 2009 Sep;11(9):2307-16
pubmed: 19309259
PLoS One. 2014 Mar 27;9(3):e93258
pubmed: 24676137
J Cardiovasc Pharmacol Ther. 2017 May;22(3):283-292
pubmed: 27909014
Invest Ophthalmol Vis Sci. 2014 Nov 20;56(1):221-31
pubmed: 25414185
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3671-6
pubmed: 18660428
J Cell Biol. 2012 Jun 25;197(7):857-67
pubmed: 22733998
Behav Brain Res. 2011 Nov 20;225(1):110-6
pubmed: 21767572
Curr Eye Res. 2018 Dec;43(12):1489-1499
pubmed: 30273053
Neuropharmacology. 2016 Nov;110(Pt B):626-632
pubmed: 26407763
Vision Res. 2006 Mar;46(6-7):902-13
pubmed: 16242750
Arch Ophthalmol. 2011 Dec;129(12):1583-91
pubmed: 22159678
Nat Neurosci. 2013 Sep;16(9):1299-305
pubmed: 23933749
Oncotarget. 2016 Nov 29;7(48):78455-78472
pubmed: 27793043
Mult Scler. 2012 Oct;18(10):1437-47
pubmed: 22354737
Mol Neurobiol. 2015;51(3):1343-52
pubmed: 25048984
Clin Ophthalmol. 2008 Dec;2(4):743-52
pubmed: 19668425
Mol Neurobiol. 2016 Sep;53(7):4713-27
pubmed: 26319559
Cell Mol Neurobiol. 2015 Aug;35(6):849-59
pubmed: 25776137
Eye (Lond). 2014 Dec;28(12):1494-501
pubmed: 25257770
FEBS J. 2019 Jan;286(2):399-412
pubmed: 29802807
Mol Med Rep. 2016 May;13(5):4386-92
pubmed: 27035223
Nat Commun. 2016 Jul 15;7:12185
pubmed: 27416896
Exp Eye Res. 2007 Mar;84(3):486-92
pubmed: 17178414
Scientifica (Cairo). 2012;2012:857516
pubmed: 24278747
Nat Neurosci. 2009 May;12(5):627-36
pubmed: 19330001
J Clin Invest. 2014 May;124(5):1956-65
pubmed: 24691439
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29
pubmed: 17565364
Prog Retin Eye Res. 2015 Mar;45:111-31
pubmed: 25529848
Br J Ophthalmol. 1974 Dec;58(12):981-9
pubmed: 4376417
Invest Ophthalmol Vis Sci. 2012 Jan 20;53(1):157-63
pubmed: 22131393
Brain Res. 2010 Jan 13;1308:158-66
pubmed: 19853589
Genes Dev. 2017 Jul 15;31(14):1417-1438
pubmed: 28860159
J Neurosci Res. 2012 Oct;90(10):1960-9
pubmed: 22674348
PLoS One. 2013 Aug 05;8(8):e69938
pubmed: 23940534
PLoS One. 2017 Jun 7;12(6):e0179042
pubmed: 28591178
J Immunol. 2003 Apr 1;170(7):3874-82
pubmed: 12646656

Auteurs

Varun Kumar (V)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Louise Alessandra Mesentier-Louro (LA)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Angela Jinsook Oh (AJ)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Kathleen Heng (K)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Mohammad Ali Shariati (MA)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Haoliang Huang (H)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Yang Hu (Y)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.

Yaping Joyce Liao (YJ)

Department of Ophthalmology, Stanford University, School of Medicine, Stanford, California, United States.
Department of Neurology, Stanford University, School of Medicine, Stanford, California, United States.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH